Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Might be better off waiting
Heard similar thoughts at 18-20 and look where ELTP is at now
Stagnant and not much direction
Why didnt ELTP make a nice bounce off the never-to-be-seen-ever-again gap close?
Come on - we are short 8 cents from where we were at the top
We can do it
Nice 150k bid at .1201. Curious if these clowns will allow it to fill.
IM LOADING UP TILL NEXT EARNINGS/ CC
YOU ??
Oh yeah, the now famous pump and dump perpetrated on innocent investors by Elite.
Is there still time left to load the boat?
I had to build it back after the Millionaire run of 2014.
This next one will be even more exciting.
GLTY
Your such an AH lol
BS would be showing up every day to a message board and not knowing why you have to be there. What's your best guess as to why you have to be here?
Investor has to be crazy patient or a crazy patient. What a difference an A makes. Not sure which I am yet. but then again catch 22.
I’m thinking your full of sht You have supposedly been topping off for 10 years Please stop the BS
If quarterly revenues average $18-20M, a fiscal year projection of $76-80M before any approvals of the current pending ANDAs, it will be hard to maintain a price below .45-50 per share in my opinion. Many will be doing the shuuda, cudda , wuddas if that projection is correct. But then again, we may be up the creek without a Kayak to mix a metaphor.
Im toppin' off for the next CC
What you doin"
"We will see a (raise) in pps"
Is that like, the third month of the year is "Marsh" ????????????
LoL LoL,
IB_🤴🏻
I disagree with that theory.
We will see a raise in pps as we get closer to the conference date. To 18-20 cents levels
Then if we have good results we could change digit.
I think the price it can achieve with a $18 to $20 million revenue is depends on what else we learn in the call. If we hear everything is going fine with generic Oxy and Vyvanse or some other unexpected event we should leap back up into the hot OTC territory. But regardless of what the short-term view you are focusing on is, this company is going to be sold in a couple of years for much more than shares are being sold at now. I am not going to hazard a guess other than to say I think it will be at least 5 times more than what it is now. To make crazy profits an investor has to be crazy patient.
What do you predict the stock price will be if the company does show $18-20M in revenue for the 4th quarter? Do you think it will stay in the .11-.13 range until the earnings are announced at the end of June some 7 weeks from now?
Nasdaq ?? This thing is going the wrong way.
Are you now on the "nasdaq" will cure every thing
wagon....???
At what point will you realize something smells
fishy. No buy out with the Mikah parasite attached to ELITE, Nasdaq not happening if this can't hold 13 pennies per share, what's next ??
This upcoming quarter needs to be more than 10% higher than the last. I think this is possible based on the idea/hope that the Prasco sales in Dec were just a small part of the full sales made to Prasco for any given quarter. Meaning that I am optimistic that shipments to Prasco made from Jan to Mar could be double or triple whatever the Dec shipment was. I think it is safe to assume the Dec shipment wasn't very large given we saw only a 10% increase in revenue (not shabby but not enough to keep investors excited in an OTC stock). Without a 20% to 30% boost in revenue ($18 to $20 million) we will stay in the 11 to 13 cent range. Yes, I'm guessing another 5.5 months (3.5 months until 10Q w/o then another 1.5 months until next Q1) news that this could go down the 11s....
In Q3 CC I see that our working capital should start increasing at a faster clip. That would not be as impactful for short term increases but should provide more stability on the share price. The longer term OTC investor takes working capital seriously and it is certainly a tangible value that can't be argued with when a company is up for sale (which we know Elite will be in the relative near-term). The following is an explanation that Carter gave
Which is it ? We go to Naz where the pos needs to be above a dollar Or do we got bought out when the pos is over a dollar Make up your mind
Hmm. I wonder if the stock will be .13 when the company announces a record quarter and record year in June. The people playing the long game should be happy to take advantage of the MMs who try to suppress the price.
Right now we do not have large institutions that maintain our price at the right level - WE, the BIG LONGS are playing that role but we do not have the deep pockets of the institutions - as soon as we move to NASDAQ, Goatland should disappear from the horizon...
Shortages:
FDA shortage link
for Adderall:
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1
FDA shortage link for Vyvance
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lisdexamfetamine%20Dimesylate%20Capsule&st=c
FDA shortage link for Concerta
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release&st=c
FDA shortage link for Naltrexone
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c
FDA shortage link for Methotrexate
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methotrexate%20Sodium%20Tablet&st=c
Jimmy Joe. I don't see Naltrex on the FDA shortage list
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c&tab=tabs-1
could be a logistic problem
What confidence would that be when MMs decide the share price should be a 6.48 P/E ratio~?
Buy back~? Dude, they are doing the right thing by getting product out on the table.
Share price will fix itself. Doubt they will be doing a buy back once they get needle movers on the table.
Unless as a "shareholder" you don't want a buyout and would rather wait~?
Fortunately you will not get the opportunity. Buyout is coming < 2 years.
Time is precious and needle movers have to have time to ramp up in sales.
You 🤡s crack me up. 😸😹😸
$ELTP baby~!
IB is one of the FUDsters along with Ama.
Let's see, Ama took out a loan to buy some shares when Elite was 18 cents~?
No complaints though paying that loan off. 🤣😂
That's what I like about these guys.... they expect longs to believe what they say as truth social.
Pun intended.
The P/E ratio is super low. Good point ko49. MMs playing games as usual.
$ELTP baby~!
Naltrexone is still on the shortage list as well~? Maybe that surprises too.
Kirkov is doing a pretty good job. Good hire no~? NH sure picked the right guy.
Great addition to the Company IMO.
Next hire for Elite should be Pavel Chekov of the Star Ship Enterprise.
Montgomery Scott aka Mr. Scott aka Scotty would also be a great hire. Maybe show Elite how to make transparent aluminum.
Doctor McCoy is too salty sometimes.
If Elite comes out with a new Viagra formulation and calls it Mydixafloppin, that would also be a plus.
$ELTP baby~!
Let’s get the Adderalls and NeedleMovers paid for.
Get rid of their minimal debt then buyback.
It’s going to be way higher than where we are..
It also sends a message of confidence in the company
That could happen after Vyvance launch in a year
Elite should follow Apples lead and do a buy back Their stock shot up 7 percent
Shortages:
FDA shortage link
for Adderall:
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Amphetamine%20Aspartate%20Monohydrate,%20Amphetamine%20Sulfate,%20Dextroamphetamine%20Saccharate,%20Dextroamphetamine%20Sulfate%20Tablet&st=c&tab=tabs-1
FDA shortage link for Vyvance
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lisdexamfetamine%20Dimesylate%20Capsule&st=c
FDA shortage link for Concerta
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methylphenidate%20Hydrochloride%20Tablet,%20Extended%20Release&st=c
FDA shortage link for Naltrexone
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Naltrexone%20Hydrochloride%20Tablet&st=c
FDA shortage link for Methotrexate
https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Methotrexate%20Sodium%20Tablet&st=c
Catalyst check off:
X 1. Cash Flow Positive Status - 5 years
X 2. Purchase building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products.
X 3. Adderall IR $335 Million Approved and Launched
X 4. Adderall XR $1.56 Billion Approved and Launched
X 5. Double digit quarterly revenues in millions
X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams
X 7. Prasco/Burel Adderall agreement starting January 1st 2024
X 8. First shipment Adderall XR to PRASCO Dec 2023
X 9. DEA increases manufacturing quotas for Adderall & Vyvance
X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023
X 11. FDA Acceptance of Generic OxyContin Sept 2023
__12. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million
X 13. Vigabatrin Approval $233 Million
X 14. Pyros Settle Vigabatrin -VigPoder trade mark challenge then LAUNCH
__15. Generic Methotrexate Approval- Antimetabolite $42 Million
__16. $50 million in yearly revenues
X 17. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs - Jan 2024
X 18. PE ratio under 7.0
__19. Generate revenues over $20 million/quarter
__20. Generic OxyContin Approval - FIRST TO FILE Aug 17, 2023 $720 Million
__21. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay
__22. European distribution - Dexcel partnership approval by Israeli Health
__23. Full ownership of Adderall IR $ 335 Million
__24. Full ownership of Adderall XR $ 1.56 Billion
__25. Generic Concerta- $1.2 BILLION FDA submission
__26. $100 million in yearly revenue
__27. Generic Vyvanse Approval and Launch
__28. $200 million in yearly revenue
__29. Deep pocket partner for SequestOx
__30. Patented Unique ADF (w/o naltrexone)-- NDA
__31. Mikah ANDA (s)
__32. Undisclosed ANDAs/NDAs
__33. DollarLand PPS
__34. Big Pharma bid
__35. Uplist to the NASDAQ Exchange
__36. ELTP Elite Pharmaceutical Buyout - less than 2 1/2 years from Feb 2024
__37. Vegas Baby !!!!!!!
Why not try that when it was 2-3 cents instead, and not 6x higher or more?
That remains the problem with this stupid theory - it makes no logical sense in $$ terms. Lol.
Well, that's not very nice but you really do not think there is a chance that Mikah will try and buy Elite ???????????
IB_🤴🏻
5-10% of $10 billion combined IMS markets
And yours just continues to be added to the ongoing childish posts…
Oh we are well over the classic "Billion" Share mark now ....................
What do you think Mikah will offer ??????????????
IB_🤴🏻
When a person is not truthful, "Hi Longs, (I have muted all the goatlanders)", nothing they post has any truthful value !!!!!!!!!!!!
You have no idea what he will do, you worship him by faith,
IB_🤴🏻
What is going to make this company worth 3.5 to 5 billion ?
He is just saying anything he can to annoy people. He doesn't even know why he has to work this board anymore. There is nothing to say based on the math and he probably knows that too.
Mikah will NEVER buy Elite - the question shows how little you understand of what is going on with this company, OR you are just playing Dumb to make 10 cents for a reply.
Mikah IS Nasrat Hakim - Nasrat Hakim will not take money from his right pocket to put it in his left pocket.
Mikah will be bought by Pfizer or Merck or another big pharma. and the price will START at $3.5 and may go up to $5.
What PPS do you think Mikah will offer for Elite ????????????
IB_🤴🏻
Good luck with that, sincely.
.52 is light years from .13 (and falling).
The CEO/owner of Mikah will never allow a PPS of .52 as long as he controlls both ends, share holders are powerless.
He's the Shepard and the lottery club members are his sheep....sad but true.
Last post today, thanks
Have a tranquil weekend
You said, "in exactly 1 year I plan to retire...4/30/2025
Better be above 30 cents by then smile" !!!!!!!!!!!!!!!!!!!!!!!
So now $0.31 is not enough ............
IB_🤴🏻
at $.52 I would retire on the spot - and keep at least half of my Eltp investment (to secure my retirement).
Schwab Users - soon T+1
https://www.schwab.com/learn/story/7-things-to-know-about-t1-settlement
Much higher volatility
I never said you were a NasRat worshipper .....................
You are The Elite Message Board, "Contrarian" !!!!!!!!!!!!!!!!!
Now reject that and prove me correct,
IB_🤴🏻
"Typically, the average P/E ratio is around 20 to 25. Anything below that would be considered a good price-to-earnings ratio, whereas anything above that would be a worse P/E ratio."
ELTP has a PE of 6.48. If ELTP had an average PE in line with the market the stock price would be around .40 to .52 per share. IMO ELTP is way undervalued.
Followers
|
962
|
Posters
|
|
Posts (Today)
|
24
|
Posts (Total)
|
399736
|
Created
|
03/24/09
|
Type
|
Free
|
Moderators jimr1717 mrwrn2010 NASDAQ2020 IB_ namtae Dr JoeBarducci |
Elite needs a Board of Directors that represents all shareholders !!!
Senior Moderator: IB_
Posted: 6/5/23
________________________________________________________________________________________________________________
Elite Pharmaceuticals, Inc. |
Website | Location | Employees | Facility | CEO |
www.elitepharma.com | Northvale, New Jersey | 53 | 55,000 sq ft | Nasrat Hakim |
Products & Pipeline | ||||
Drug | Market Size | Status | Competitors | Marketed By |
Adderall IR | 389.8 M | On Market | 15 | Elite |
Adderall XR | 1.56 B | On Market | 10 | Elite & Prasco |
Dantrolene | 6.3 M | On Market | 2 | Elite |
Isradipine | 5.5 M | On Market | 1 | Elite |
Loxapine | 5 M | On Market | 2 | Elite |
Phendimetrazine | 4.5 M | On Market | 4 | Elite |
Trimipramine | 2 M | On Market | 1 | Elite |
Naltrexone | 16 M | On Market | 5 | Precision Dose |
Phentermine Capsules | 7.5 M | On Market | 6 | Precision Dose |
Phentermine Tablets | 40 M | On Market | 8 | Precision Dose |
Vigabatrin | 233.7 M | On Market | 13 | Pyros |
Doxycycline | 85 M | Approved (Discontinued) | 9 | ---------- |
Tylenol with Codeine | 45 M | Approved (On Hold - Opioid) | 5 | ---------- |
Dopamine Agonist | 12 M | Filed with FDA - 22 Dec 2022 | ---------- | ---------- |
Antimetabolite | 42 M | Filed with FDA - 20 Apr 2023 | ---------- | ---------- |
Generic OxyContin | 720 M | Filed with FDA - 17 Aug 2023 | ---------- | ---------- |
Generic Vyvanse | 5.1 B | Filed with FDA - 21 Dec 2023 | 14 | ---------- |
Generic Concerta | 1.16 B | In Development (Final Stages) | 9 | ---------- |
Financials | ||||
Fiscal Year | Revenue | Change | Net Income | Change |
2019 | 7,568,508 | ---------- | (9,279,321) | ---------- |
2020 | 17,994,639 | +137.76% | (2,240,351) | +75.86% |
2021 | 25,380,749 | +41.05% | 5,088,421 | +327.13% |
2022 | 32,262,117 | +27.11% | 8,898,245 | +74.87% |
2023 | 34,155,114 | +5.87% | 3,561,846 | -59.97% |
2024 Q1 | 8,980,076 | +17.04% | 1,141,809 | +273.28% |
2024 Q2 | 14,157,185 | +64.90% | 14,934,601 | +866.0% |
2024 Q3 | 15,538,800 | +68.00% | 3,500,000 | +80.0% |
FY 2024 Projected | Minimum Projected: 50,000,000 | Minimum YOY Projected Increase of 68.31% | ||
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |